80 related articles for article (PubMed ID: 23176590)
1. Economic impact of antidepressant treatment duration in naturalistic conditions.
Tournier M; Crott R; Gaudron Y; Verdoux H
Acta Psychiatr Scand; 2013 May; 127(5):365-72. PubMed ID: 23176590
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
[TBL] [Abstract][Full Text] [Related]
3. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.
Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J
J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach.
Béland SG; Tournier M; Galbaud du Fort G; Crott R; Ducruet T; Pariente A; Moride Y
Value Health; 2011 Jun; 14(4):492-8. PubMed ID: 21669374
[TBL] [Abstract][Full Text] [Related]
5. Childhood predictors of use and costs of antidepressant medication by age 24 years: findings from the Finnish Nationwide 1981 Birth Cohort Study.
Gyllenberg D; Sourander A; Niemelä S; Helenius H; Sillanmäki L; Ristkari T; Piha J; Kumpulainen K; Tamminen T; Moilanen I; Almqvist F
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):406-15, 415.e1. PubMed ID: 21421180
[TBL] [Abstract][Full Text] [Related]
6. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
7. [The costs of depression and the cost-effectiveness of treatment].
König HH; Luppa M; Riedel-Heller S
Psychiatr Prax; 2010 Jul; 37(5):213-5. PubMed ID: 20597034
[No Abstract] [Full Text] [Related]
8. [Antidepressants consumption in the global population in France].
Olié JP; Elomari F; Spadone C; Lépine JP
Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
10. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
11. Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment.
Verdoux H; Cougnard A; Thiébaut A; Tournier M
Pharmacopsychiatry; 2011 May; 44(3):96-101. PubMed ID: 21328195
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus.
Simon GE; Katon WJ; Lin EH; Rutter C; Manning WG; Von Korff M; Ciechanowski P; Ludman EJ; Young BA
Arch Gen Psychiatry; 2007 Jan; 64(1):65-72. PubMed ID: 17199056
[TBL] [Abstract][Full Text] [Related]
13. Impact of initial treatment outcome on long-term costs of depression: a 3-year nationwide follow-up study in Taiwan.
Pan YJ; Knapp M; McCrone P
Psychol Med; 2014 Apr; 44(6):1147-58. PubMed ID: 23866061
[TBL] [Abstract][Full Text] [Related]
14. Impact of drug treatment history on comparative effectiveness research in schizophrenia.
McCombs J; Zolfaghari S; Ganapathy V
Value Health; 2011; 14(5):679-86. PubMed ID: 21839406
[TBL] [Abstract][Full Text] [Related]
15. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder.
Zhu B; Zhao Z; Ye W; Marciniak MD; Swindle R
J Nerv Ment Dis; 2009 Feb; 197(2):136-9. PubMed ID: 19214050
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant therapy during pregnancy: an insight on its potential healthcare costs.
Ramos E; Ofori B; Oraichi D; Bérard A
Can J Clin Pharmacol; 2008; 15(3):e398-410. PubMed ID: 18953084
[TBL] [Abstract][Full Text] [Related]
17. Are psychological treatments for depression in primary care cost-effective?
Bosmans JE; van Schaik DJ; de Bruijne MC; van Hout HP; van Marwijk HW; van Tulder MW; Stalman WA
J Ment Health Policy Econ; 2008 Mar; 11(1):3-15. PubMed ID: 18424872
[TBL] [Abstract][Full Text] [Related]
18. [Duration of antidepressant drug treatment and its determinants in France].
Tournier M; Cougnard A; Boutouaba-Combe S; Verdoux H
Encephale; 2011 May; 37 Suppl 1():S36-41. PubMed ID: 21600331
[TBL] [Abstract][Full Text] [Related]
19. Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.
Yu AP; Ben-Hamadi R; Wu EQ; Kaltenboeck A; Bergman R; Xie J; Blum S; Erder MH
J Med Econ; 2011; 14(4):508-15. PubMed ID: 21692605
[TBL] [Abstract][Full Text] [Related]
20. Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees.
Hankin CS; Koran L; Sheehan DV; Hollander E; Culpepper L; Black DW; Knispel J; Dunn J; Dougherty DD; Bronstone A; Wang Z
Ann Clin Psychiatry; 2011 Nov; 23(4):285-96. PubMed ID: 22073386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
